Table 3.

Characteristics of 23 patients with HMPV lower respiratory tract disease, according to ribavirin therapy.

Characteristic	Treated with ribavirin (n=10)	No ribavirin (n=13)
Underlying disease
Acute leukemia	4 (40%)	4 (31%)
HD/MM/NHL	3 (30%)	6 (46%)
CML	1 (10%)	0 (0%)
CLL	0 (0%)	3 (23%)
Other	2 (20%)	0 (0%)
Donor type
Matched related	1 (10%)	1 (8%)
Mismatched/unrelated	5 (50%)	7 (55%)
Autologous	1 (10%)	2 (15%)
Pre-transplant	3 (30%)	3 (22%)
Acute GVHD *	3 (50%)	7 (88%)
Median days post HCT *	18	124
Ventilated at diagnosis	3 (30%)	2 (15%)

HD, Hodgkin disease; MM, multiple myeloma; NHL, non-hodgkin lymphoma; CML, chronic myelogenous leukemia, CLL, chronic lymphocytic leukemia; GVHD, graft-versus-host disease; HCT, hematopoietic cell transplantation

^*Allogeneic recipients only